Associated Papers
Hedgehog signalling pathway inhibitors in the treatment of basal cell carcinoma: an updated review.
Markota Cagalj A et al.
Journal of Drug Targeting, 2025
ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling - a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial.
Kringelbach T et al.
Bmc Cancer, 2023
The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An In Silico Study.
Punta M et al.
Frontiers in Immunology, 2020
33133066 (PubMed )
Supplement: Table_1.xlsx › Resistance-no-BCR-ABL1
SOX9 Transcriptionally Regulates mTOR-Induced Proliferation of Basal Cell Carcinomas.
Kim AL et al.
The Journal of Investigative Dermatology, 2018
A computational study of hedgehog signalling involved in basal cell carcinoma reveals the potential and limitation of combination therapy.
Buetti-Dinh A et al.
Bmc Cancer, 2018
Reprogramming Medulloblastoma-Propagating Cells by a Combined Antagonism of Sonic Hedgehog and CXCR4.
Ward SA et al.
Cancer Research, 2017
AKT1 Activation is Obligatory for Spontaneous BCC Tumor Growth in a Murine Model that Mimics Some Features of Basal Cell Nevus Syndrome.
Kim AL et al.
Cancer Prevention Research (philadelphia, Pa.), 2016
Rolling the Genetic Dice: Neutral and Deleterious Smoothened Mutations in Drug-Resistant Basal Cell Carcinoma.
Atwood SX et al.
The Journal of Investigative Dermatology, 2015
Common Variants Affecting Susceptibility to Develop Multiple Basal Cell Carcinomas.
Verkouteren JAC et al.
The Journal of Investigative Dermatology, 2015
Smoothened variants explain the majority of drug resistance in basal cell carcinoma.
Atwood SX et al.
Cancer Cell, 2015
Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma.
Yauch RL et al.
Science (new York, N.y.), 2009
Select a paper to view details